BiomX Inc. (NYSE:PHGE) on Tuesday announced that the U.S. Food and Drug Administration (FDA) is continuing its evaluation of the nebulizer device used for drug administration in the company's Phase 2b trial of BX004 in cystic fibrosis patients.PHGE shares are retreating from recent levels. See the complete data hereThe company is working with the third-party manufacturer to address recent FDA follow-up information requests in order to lift the FDA's clinical hold with respect to the trial.The FDA has placed ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .It is difficult to believe we are already at Thanksgiving Day in 2025. Where does the time go? The markets have continued to rally as they have since late 2022, with the debut of ChatGPT. The market had oneBret Jensen has over 13 years ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.When they are doing well, some of the investments and opportunities are equal parts beaut ...

SciSparc Ltd. (NASDAQ:SPRC) ) traded higher in Wednesday's premarket after moving to acquire key endoscopy intellectual property from Xylo Technologies Ltd.The deal signals a strategic expansion beyond its core neuroscience pipeline into medical device commercialization.Strategic IP AcquisitionSciSparc signed a binding term sheet to purchase a portfolio of patents, trademarks and know-how linked to advanced endoscopic imaging systems. The transaction centers on the MUSE platform, a single-use device for tra ...

Core Viewpoint - The article emphasizes the importance of confirming the sustainability of stock trends for successful short-term investing, highlighting that price movements should be supported by strong fundamentals and positive earnings estimates [1][2]. Group 1: Stock Performance - Bright Minds Biosciences Inc. (DRUG) has shown a significant price increase of 68.9% over the past 12 weeks, indicating strong investor interest [4]. - In addition to the long-term trend, DRUG has experienced a price increase of 14.1% over the last four weeks, suggesting that the upward trend is still intact [5]. - DRUG is currently trading at 90% of its 52-week high-low range, indicating a potential breakout opportunity [5]. Group 2: Fundamental Strength - DRUG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, which are critical for near-term price movements [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term performance [7]. Group 3: Investment Strategy - The article suggests utilizing the "Recent Price Strength" screen to identify stocks like DRUG that are on an upward trend supported by strong fundamentals [3][8]. - It also mentions that there are over 45 Zacks Premium Screens available for investors to find stocks that align with their investment strategies [8].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Skye to Contact Him Directly to Discuss Their OptionsIf you purchased or acquired securities in Skye between November 4, 2024 and October 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - November 26, 2025) - ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - November 26, 2025) - Faruqi & Faruqi, ...

Core Viewpoint - Mural Oncology plc has finalized the cash consideration for its shareholders at $2.035 per share as part of the acquisition by XOMA Royalty Corporation, with the additional price per share determined to be $0.000 [1][2]. Group 1: Acquisition Details - The acquisition involves XOMA Royalty's wholly-owned subsidiary, XRA 5 Corp., acquiring the entire issued and to be issued share capital of Mural under an Irish High Court sanctioned scheme of arrangement [2]. - The acquisition is expected to close in early December 2025, pending the satisfaction of closing conditions and the sanction of the scheme by the Irish High Court [3]. Group 2: Financial Implications - The total cash consideration payable to Mural shareholders upon closing of the acquisition will be $2.035 per share [1].

ESTERO, FL / ACCESS Newswire / November 26, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, has expanded its scientific team with the November 4, 2025 addition of Mark J. Jaroszeski, PhD, a tenured professor in the Department of Medical Engineering at the University of South Florida. ...

Accessibility StatementSkip Navigation ATYR Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, Nov. 26, 2025 /PRNewswire/ -- The financial and legal pressures on aTyr Pharma, Inc. (NASDAQ: ATYR) intensified earlier this month as the clinical-stage biotech company reported third-quarter results on Nov. 6 that missed Wall Street estimates, all while navigating high-stakes securities class action litigation. Global plaintiffs' rights firm Hagens Berman has been investigating the alleged claim ...